Your browser is no longer supported. Please, upgrade your browser.
Settings
TAK Takeda Pharmaceutical Company Limited daily Stock Chart
TAK [NYSE]
Takeda Pharmaceutical Company Limited
Index- P/E20.28 EPS (ttm)0.81 Insider Own44.13% Shs Outstand3.10B Perf Week-1.56%
Market Cap51.08B Forward P/E- EPS next Y- Insider Trans- Shs Float3.00B Perf Month-2.20%
Income- PEG289.76 EPS next Q- Inst Own- Short Float0.12% Perf Quarter-7.06%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.49 Perf Half Y-17.54%
Book/sh12.55 P/B1.31 EPS next Y- ROA- Target Price23.64 Perf Year-21.02%
Cash/sh- P/C- EPS next 5Y0.07% ROE- 52W Range15.50 - 21.95 Perf YTD-2.14%
Dividend0.83 P/FCF- EPS past 5Y- ROI- 52W High-25.01% Beta-
Dividend %5.04% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low6.19% ATR0.32
Employees49578 Current Ratio- Sales Q/Q88.80% Oper. Margin- RSI (14)36.75 Volatility1.34% 1.70%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.22 Prev Close16.60
ShortableYes LT Debt/Eq- EarningsAug 13 BMO Payout- Avg Volume1.44M Price16.46
Recom1.50 SMA20-4.26% SMA50-5.42% SMA200-11.60% Volume1,768,652 Change-0.84%
Aug-15-19Downgrade Daiwa Securities Outperform → Neutral
Aug-21-19 08:40PM  Somerville's Finch raises $53M to develop bacteria pills for C.diff, autism American City Business Journals
Aug-16-19 09:30AM  Is Takeda (TAK) a Profitable Stock for Value Investors Now? Zacks
Jul-31-19 02:00AM  Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year Business Wire
02:00AM  Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration Business Wire
Jul-24-19 03:29PM  How Do Earnings Impact The Stock Market? Zacks
Jul-23-19 10:18AM  The AbbVie-Allergan Merger Is the Most Positive of the Pharma Deals Barrons.com
Jul-22-19 01:00AM  Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease Business Wire
Jul-17-19 12:57PM  Takeda kicks off sale of Western European drugs: sources Reuters
10:58AM  Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks
Jul-16-19 01:15PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-15-19 05:59PM  J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks
Jul-09-19 09:00PM  Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index Business Wire
02:15PM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
11:30AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-08-19 02:00AM  Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A Business Wire
Jul-03-19 09:50AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
07:00AM  Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019 Business Wire
Jul-02-19 11:53AM  Marshall Waces Return, AUM, and Holdings (Part II) Insider Monkey
11:30AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-01-19 04:31PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire
02:20PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
11:30AM  Takeda Completes Sale of Xiidra® to Novartis Business Wire
09:26AM  Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status Zacks
Jun-28-19 08:00PM  AbbVie Is Buying Allergan. Thats Not the Right Remedy for the Stock. Barrons.com
04:01PM  J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma Zacks
03:20PM  SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK PR Newswire
03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK CNW Group
01:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
02:00AM  Pharma-owned plasma center set for major expansion in metro Phoenix American City Business Journals
Jun-27-19 08:05PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
06:45PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
04:49PM  T. Rowe Price Japan Fund Comments on Takeda Pharmaceutical GuruFocus.com
01:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
12:46PM  5 stocks trading at under $10 worth discovering MarketWatch
08:00AM  Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2018 Business Wire
05:22AM  Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries Business Wire
Jun-25-19 07:22PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
06:03PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Takeda Pharmaceutical Company Limited TAK Business Wire
04:36PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire
10:11AM  AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study Zacks
01:03AM  Asian markets pull back ahead of Trump-Xi meeting at G-20 MarketWatch
Jun-24-19 08:33AM  Verastem Up on Positive Data From Early-Stage Copiktra Study Zacks
Jun-21-19 01:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
Jun-11-19 01:49PM  Hedge Funds Have Never Been This Bullish On Takeda Pharmaceutical Company Limited (TAK) Insider Monkey
12:01AM  Hudson Bay Capital Managements Return, AUM, and Holdings Insider Monkey
Jun-07-19 12:05PM  Seth Klarman's Favorite Biotech Positions GuruFocus.com
Jun-06-19 07:37AM  The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
Jun-05-19 04:30PM  Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis Business Wire
Jun-03-19 04:00PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) GlobeNewswire
09:00AM  Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib) Business Wire
07:15AM  New Ad-hoc Analysis of Phase 3 HELP Study Evaluates Prevention of HAE Attacks with TAKHZYRO® (lanadelumab) During Early Treatment Phase Business Wire
Jun-02-19 09:00PM  Takeda Makes First Private Sector Pledge for Global Fund Replenishment Business Wire
May-28-19 05:19AM  Tudor Investments Latest Moves Insider Monkey
May-22-19 05:55PM  Larry Robbins' Top 6 Buys of the 1st Quarter GuruFocus.com
May-21-19 06:55PM  John Paulson's Top 5 Buys in the 1st Quarter GuruFocus.com
10:54AM  BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial Benzinga
May-17-19 01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
07:30AM  The Allure of Japanese Stocks Barrons.com
May-16-19 05:38PM  Why this startup's $140 million financing is easy to digest American City Business Journals
05:05PM  Seth Klarman Introduces 7 New Positions in 1st Quarter GuruFocus.com
03:00PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) GlobeNewswire
02:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire
01:35PM  Japan's Takeda expects binding offers for Latam business by end of May -sources Reuters
12:10PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
12:00PM  Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses Business Wire
08:00AM  Takeda to Highlight Compelling New Data and Portfolio Advances for Gastrointestinal (GI) Diseases at DDW 2019 PR Newswire
02:00AM  Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health" Business Wire
May-15-19 08:30AM  Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals Business Wire
08:00AM  Takeda Celebrates MPS Awareness Day in Recognition of the Seven Rare MPS Diseases PR Newswire
03:05AM  Nikkei snaps 7-day losing streak helped by China's stimulus hopes Reuters
01:00AM  Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting Business Wire
May-14-19 11:04PM  Nikkei hobbled by trade worries, disappointing earnings Reuters -8.06%
04:25PM  Takeda Dives After Guiding To Losses Following Shire Megamerger Investor's Business Daily
06:45AM  Japan's Takeda forecasts surprise annual loss on Shire-related costs Reuters
03:31AM  Takeda forecasts operating loss as Shire integration costs mount Financial Times
02:00AM  Takeda Reports FY2018 Full Year Results and Issues FY2019 Guidance Business Wire
May-13-19 06:47PM  Kamada (KMDA) to Report Q1 Earnings: What's in the Cards? Zacks
May-09-19 02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
11:10AM  Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal TheStreet.com
07:46AM  These 3 revolutionary genomics companies are changing lives for patients and investors MarketWatch
07:22AM  Novartis buys dry eye drug from Takeda for up to $5.3 billion Reuters
07:00AM  U.S. Food & Drug Administration Accepts Takedas Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis Business Wire
06:11AM  Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal Bloomberg
05:51AM  Novartis buys dry eye drug from Takeda for up to $5.3 billion Reuters
05:43AM  Takeda sheds products, 485 jobs in deals worth $5.7B American City Business Journals
May-08-19 09:34PM  Takeda to sell eye drug to Novartis in $5.3bn deal Financial Times
07:38PM  Novartis buys Takeda's dry eye drug for $3.4 bln Reuters
06:48PM  Novartis buys dry-eye drug Xiidra rights from Takeda for $3.4 billion MarketWatch
06:38PM  Novartis buys Takeda's dry eye drug for $3.4 bln Reuters
06:30PM  Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures Business Wire
May-07-19 10:00AM  Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes Business Wire
May-01-19 09:26AM  What's in the Cards for Sunesis (SNSS) This Earnings Season? Zacks
06:20AM  After Takeda merger, Shire exec jumps to top post at Sobi American City Business Journals
Apr-30-19 10:30AM  Takeda Opens New Global Research Center in San Diego Business Wire
Apr-29-19 09:15AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
Apr-26-19 01:11PM  Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark Zacks
Apr-25-19 10:04AM  Top Ranked Income Stocks to Buy for April 25th Zacks
Apr-18-19 06:42PM  T. Rowe Price Japan Fund's Top 5 Buys in 1st Quarter GuruFocus.com
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. It provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. The company operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. Takeda Pharmaceutical Company Limited has licensing agreements with TESARO, Inc. for the commercialization and clinical development of Niraparib, a novel poly ADP-ribose polymerase inhibitor; Denali Therapeutics for neurodegenerative disease therapeutic product candidates; and Wave Life Sciences Ltd. for central nervous system nucleic acid therapies. The company also has collaboration agreements with Rani Therapeutics LLC to conduct research on the use of the RANI PILL technology for oral delivery of Factor VIII therapy for patients with hemophilia A; Novimmune S.A. to develop and commercialize a bi-specific antibody to treat hemophilia A and hemophilia A patients with inhibitors; and AB Biosciences Inc. for a recombinant immunoglobulin product candidate and intellectual property relating to its pan receptor interacting molecule program. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.